AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02099656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Asthma Controller Medication
Description: Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
Study NCT02099656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Second Asthma Controller Medication
Description: Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
Study NCT01489163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
Study NCT01025921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colistin (Tadim)
Description: 500.000 units of inhaled colistin three times daily for 10 days
Study NCT01713374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold pressure test
Description: A hand will be placed in ice-cold water.
Study NCT05208398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 5 mg twice daily, on top of standards of care.
Study NCT05208398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations
Study NCT00739830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: 40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
Study NCT00739830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medroxyprogesterone acetate tablets OR megestrol acetate
Description: oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
Study NCT00739830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
Study NCT01678586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: In true acupuncture the needles penetrate the skin.
Study NCT01678586 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: In sham acupuncture the needles do not penetrate the skin.
Study NCT01092247 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional support with Standard diet
Description: Nutritional support with Standard diet
Study NCT01092247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention with the Ketogenic diet
Description: Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
Study NCT02513524 — intervention group
Intervention type: PROCEDURE
Intervention: Direct Observed Therapy test
Description: There is one group only, all of whom will undergo direct observed therapy testing
Study NCT02537418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Study NCT02537418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Study NCT01025921 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: inhaled normal saline
Description: inhalation of 2,5cc Normal Saline via nebulisation
Study NCT05280522 — intervention group
Intervention type: OTHER
Intervention: Volitional Contractions (VOL)
Description: Participants are provided visual feedback showing the 20% MVIC force and instructed to produce the target force for 10 s then relax for 50 s. The timing is provided by the research personnel until 10 contractions are completed. Participants rate their pain during each contraction on a visual analog scale. The pain ratings are averaged across all 10 contractions and the average is used in the analysis.
Study NCT05280522 — intervention group
Intervention type: DEVICE
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: Participants are instructed to relax throughout the NMES contractions. The amplitude of the stimulation is increased until 20 percent MVIC force is achieved and the amplitude is recorded. The timing of the NMES is 12 s on: 50 s off for 10 contractions. The on-time included a 2s ramp up to the target amplitude. Participants rate their pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 contractions and the average was used in the analyses.
Study NCT05280522 — intervention group
Intervention type: DEVICE
Intervention: Noxious Electrical Stimulation (NXES)
Description: The intensity of the electrical stimulation is increased slowly over 30 s to the maximum tolerated level. Trains of NXES are delivered at the maximum tolerated intensity with a timing ratio of 12 s on: 50 s off for a total of 10 trains. The on-time included a 2s ramp up to the target amplitude. Participants rate the pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 trains of NXES and the average is used in the analyses.
Study NCT03896971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of thrombopoietin mimetic and cyclosporin A
Description: This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
Study NCT03746132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EPIFLO
Description: EPIFLO is a 3 ounce oxygen generator that continuously delivers 3 ml/hr of pure oxygen to the wound site, to enable tissue regenerative processes, thus driving closure of delayed-healing acute or chronic wounds.
Study NCT02699294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual pressure release
Description: Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
Study NCT02892331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training (MOD-INT)
Description: Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max. The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
Study NCT02699294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contract-relax PNF stretch
Description: Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
Study NCT02699294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Z-stretch
Description: Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
Study NCT00791791 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standardized pain stimulus
Description: a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
Study NCT02892331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity exercise training (HI-INT)
Description: Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment). The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
Study NCT03858387 — intervention group
Intervention type: DRUG
Intervention: Meropenem
Description: This group is composed of 52 critically ill patients, meropenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2.5 h, 2.5-4 h, 4-8 h or 4-12 after meropenem administration.
Study NCT03858387 — intervention group
Intervention type: DRUG
Intervention: Imipenem
Description: This group is composed of 50 critically ill patients, imipenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h or 4-12 after imipenem administration.
Study NCT03343769 — intervention group
Intervention type: OTHER
Intervention: BERG scale
Description: Complete the BERG balance scale
Study NCT03343769 — intervention group
Intervention type: OTHER
Intervention: Functional tests
Description: timed up and go, Mini motor test, retropulsion test
Study NCT03343769 — intervention group
Intervention type: OTHER
Intervention: Measurement of balance on a force platform
Description: 4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)
Study NCT03343769 — intervention group
Intervention type: OTHER
Intervention: Measurement of maximal moment of the plantar flexor and dorsiflexor muscles
Description: 5-second repetitions
Study NCT00494416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: delivery approaches of malaria intermittent preventive treatment in pregnancy
Description: Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.~Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs).
Study NCT04332991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.
Study NCT04332991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
Study NCT01684345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous injection
Study NCT01684345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 gevokizumab
Description: Solution for subcutaneous injection
Study NCT01684345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 gevokizumab
Description: Solution for subcutaneous injection
Study NCT02246647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Permeability measurement
Description: Saccharide excretion was compared between IBS-C and healthy volunteers
Study NCT02246647 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagogastroduodenoscopy
Description: Duodenal biopsies were collected from IBS-C and healthy volunteers
Study NCT02246647 — intervention group
Intervention type: PROCEDURE
Intervention: Flexible sigmoidoscopy
Description: Colonic biopsies were collected from IBS-C and healthy volunteers
Study NCT03889327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological Feedback & Psychoeducation (Cognition)
Description: The customary practice of providing feedback on neuropsychological test performance can address patient misperceptions of cognitive impairment by distinguishing between perceived and objective neuropsychological test performance. Explaining how normative data is derived by comparison to same age peers, patients are able to better understand their current cognitive functioning. The proposed intervention will employ both psychoeducation and neuropsychological feedback for participants assigned to the treatment group, and psychoeducation for participants assigned to the control group. Both groups will watch 3 brief videos (exactly the same length in time) and answer two qualitative questions following each video.
Study NCT03889327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation (Health)
Description: Information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The control intervention will include expert testimony from a nutritionist and expert dietician.
Study NCT03854903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is taken orally.
Study NCT02325752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: A multidisciplinary team delivered the transitional care program.~Our transitional care program focused on four key areas:~1. Post discharge surveillance of the patient to ensure adherence to care plans.~2. Coordination of follow-up visits with specialist care providers.~3. Patent education and care giver training.~4. Activation of community and social services.~Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge.
Study NCT01852851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Employment and Arthritis: Making it Work
Description: A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
Study NCT01678586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin is a commonly prescribed drug used to treat neuropathic pain.
Study NCT01678586 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Gabapentin
Description: Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)
Study NCT03526549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCH-aaes
Description: Administered to participants who qualified for, and opted for, retreatment.
Study NCT03526549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: No treatment administered during 180 days of observation.
Study NCT03526549 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: No treatment administered during 180 days of observation.
Study NCT02748096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Specific Instrumentation
Description: Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
Study NCT02748096 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Instrumentation
Description: Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
Study NCT02182076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBF 1120
Description: 150 mg of BIBF 1120 ES soft gelatine capsules
Study NCT02182076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: 150 mg of BIBF 1120 ES soft gelatine capsules
Study NCT02648646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme and Walk with Ease
Description: The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
Study NCT00869362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes management team
Description: MD evaluation followed by NP education and and medication titration
Study NCT03772210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Current will be administered to subject groups as specified in arm descriptions.
Study NCT03772210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Current will be administered to subject groups as specified in arm descriptions.
Study NCT03772210 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Apparent Stimulation administered
Study NCT02253849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Study NCT02253849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT02253849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT01545375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A
Description: 4 doses administered intramuscularly
Study NCT01545375 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 doses administered intramuscularly
Study NCT01545375 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Prevnar 13®
Description: 4 doses administered intramuscularly
Study NCT01545375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13®
Description: 4 doses administered intramuscularly
Study NCT01545375 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PedvaxHIB®
Description: 4 doses administered intramuscularly
Study NCT01545375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PedvaxHIB®
Description: 4 doses administered intramuscularly
Study NCT01407627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Description: Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d
Study NCT01407627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d
Study NCT00939861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy
Description: colorectal resection
Study NCT00939861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy
Description: colorectal resection
Study NCT03053102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Danicopan was administered as multiple oral doses over a period of at least 28 days.